Axsome Therapeutics, Inc AXSM

Axsome Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica. La empresa se dedica al desarrollo de terapias para el manejo de trastornos del sistema nervioso central (SNC), incluido el dolor. Opera en el negocio del desarrollo de terapias novedosas para el segmento de trastornos del SNC. Su candidato a producto, AXS-02 (tetrahidrato de zoledronato disódico), es un tratamiento oral, dirigido y no opioide para el dolor crónico. Está desarrollando AXS 02 para el tratamiento del dolor en más de tres condiciones, como el síndrome de dolor regional complejo (SDRC); la osteoartritis de rodilla (OA) asociada con lesiones de médula ósea (BML) y el dolor crónico de espalda baja (CLBP), asociado con cambios Modic (MC) de tipo I, o mixtos de tipo I y tipo II. Su candidato a producto, AXS 05, es una combinación de dosis fija de dextrometorfano (DM) y bupropión. Está desarrollando AXS 05 para el tratamiento de más de dos condiciones, como la depresión resistente al tratamiento (TRD) y la agitación en pacientes con enfermedad de Alzheimer (AD).

• Zacks Investment Research 9 sept

  Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

  Axsome Therapeutics reported Q2 2026 earnings that met EPS estimates but missed revenue expectations at $218.4M vs. $225M consensus. While lead drug Auvelity drove strong 51% YoY sales growth to $180.3M and Sunosi performed well, newest drug Symbravo significantly underperformed at $2.3M against $7.2M estimates. Post-earnings, analyst estimates have trended downward, and the stock has underperformed the S&P 500 by 3.7% over the past month.

  

• GlobeNewswire Inc. 3 sept

  PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

  PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.

  

• Zacks Investment Research 1 sept

  Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

  Axsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.

  

• GlobeNewswire Inc. 14 jul

  Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

  Axsome Therapeutics announced it will report Q2 2026 financial results on August 10, 2026, followed by a management conference call at 8:00 a.m. ET. The company is advancing its CNS disorder treatment portfolio with FDA-approved products including SUNOSI, AUVELITY, and SYMBRAVO, while progressing multiple clinical trials including Phase 3 FOCUS-2 and FOCUS-3 trials for solriamfetol in pediatric and adolescent ADHD patients.

  

• The Motley Fool 6 jul

  These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

  Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.